secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ginkgo Bioworks Holdings, Inc. (DNA)
CIK:        0001830214
Form:       8-K/A
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001628280-24-036226
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 2.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ginkgo Q2 revenue down 30% to $56M, launches RIF cutting 35% of workforce for >$85M annual savings
--------------------------------------------------------------------------------

- Q2 total revenue $56M vs $81M YoY; Cell Engineering $36M (-20%), Biosecurity $20M (41% gross margin).
- Loss from ops $(223)M incl. $72M restructuring costs; Adjusted EBITDA $(99)M vs $(80M) prior year.
- Reduction in force impacting 35% of workforce, expected to yield >$85M annualized savings by mid-2025.
- Restructuring costs estimated $18-22M in Cell Engineering; facilities consolidation underway.
- FY 2024 outlook reaffirmed: total revenue $170-190M, Cell Engineering $120-140M, Biosecurity ≥$50M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1830214/000162828024036226/0001628280-24-036226-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1830214/000162828024036226/dna-20240509.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-036226

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer